Background: Treatment of vitiligo is still a challenge in dermatology. Literature is sparse on
the definitive clinical role of basic fibroblast growth factor (bFGF) in vitiligo patients. Aims: We …

Background Vitiligo, a chronic autoimmune depigmenting skin disease, affects a significant
portion of the global population. One of the topical treatment options for vitiligo is basic …

Vitiligo is common acquired pigmentary disorder affecting skin of 1% of the world population,
India 3% to 8% incidences approximately. Treatment is tough challenge. The combination …

ABSTRACT Background: Basic Fibroblast growth factor (bFGF) increases proliferation of
melanocytes in the pigmentation of vitiligous area. Tacrolimus is well established topical …

Vitiligo is an acquired disorder of depigmentation affecting 0.1%-2% of the world's
population without discrimination of race, age and gender. The disease is characterized by …

Background: Phototherapy in its different forms, is mainstay of vitiligo management.
Combining treatment modalities like topical calcipotriol (for quicker, more intense …

Back ground: Topical application of bFGF related deca peptide followed many hours after
with sun/UVA exposure was found effective in the earlier conducted clinical trials to treat …

Background/purpose Vitiligo remains a major challenge in dermatology. However, much of
the treatment remains unclear, because little evidence is available. We sought to answer …

Vitiligo is a cosmetically disfiguring acquired disorder of pigmentation presenting with well-
defined milky-white depigmented macules. It is one of the most common pigmentary …

Vitiligo is a common, acquired, often familial melanocytopenic disorder with focal
depigmentation of skin; there are several new treatments which appear to have a higher …